ASCO GU 2020
ASCO GU 2020 Prostate Cancer
- ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial
- ASCO GU 2020: A Phase II Study of Talazoparib in Men with DNA Damage Repair Mutations and Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2020: Assessment of Inherited DNA Repair Defects in African-American and Caucasian Men with Prostate Cancer
- ASCO GU 2020: Phase Ib Study of Niraparib plus Androgen Receptor-Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2020: Phase II Study of Cabazitaxel plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2020 Kidney Cancer
- ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective
- ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Pathologists Perspective
- ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial
- ASCO GU 2020: The Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
- ASCO GU 2020: A Phase I/II Study of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cancer that Progressed on Prior Anti-Angiogenic Therapy
ASCO GU 2020 Bladder Cancer
- ASCO GU 2020: Results from BLASST-1 - Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy.
- ASCO GU 2020: Combining Chemotherapy with Novel Agents, Opportunities, and Challenges.
- ASCO GU 2020: (NEO-BLADE) Phase II Randomized Placebo-Controlled Neoadjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer
- ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma
- ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients.
ASCO GU 2020 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2020: Can Advanced Seminoma be Managed with a Risk Stratified Approach?
- ASCO GU 2020: Evaluation of the Oncologic Benefit of Adjunctive Surgery at Time of Post-Chemotherapy Retroperitoneal Lymph Node Dissection
- ASCO GU 2020: Intravesical Irrigation to Prevent Early Bladder Recurrence in Patients Undergoing Laparoscopic Radical Nephroureterectomy for Upper Urinary Tract Cancer
- ASCO GU 2020: Atezolizumab Therapy for Upper Tract Urothelial Carcinoma: Subgroup Analysis of the Single-Arm International SAUL Study in Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
- ASCO GU 2020: Prognostic Factors in Advanced Seminoma — Analysis from the IGCCCG Update Consortium.
ASCO GU 2020 Press Releases
- ASCO GU: Real World Study Finds Adding Immunotherapy Reduces Death by 45% in Advanced Prostate Cancer
- Bristol-Myers Squibb Shares Long-Term Survival Results for Nivolumab with or without Ipilimumab in Renal Cell Carcinoma
- Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® at ASCO GU 2020
- Bayer to Highlight Data from its Expanding Cancer Portfolio at 2020 ASCO GU Cancers Symposium
- miR Scientific Presents Breakthrough New Data on the miR Scientific Sentinel™ Tests for the Detection and Classification of Prostate Cancer at ASCO GU 2020